Monday, July 1, 2013
Marketed anticoagulants including warfarin and antiplatelet
therapies are used to prevent thrombosis, but they also have dose-dependent
increases in the risk of major bleeding. XO1 Ltd.
is developing a mAb targeting an allosteric site on thrombin that has the
potential to provide anticoagulation without increasing the risk of
generally resigned to the fact that it would likely be impossible to dissociate
anticoagulation from bleeding risk," said XO1 CEO and Index Venture
Partner David Grainger. But a chance clinical observation paired with
corroborating in vivo data suggests XO1's ichorcumab might be able to
separate the two effects.